News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioDelivery Sciences International (BDSI) Remains on Schedule for December ONSOLIS Resubmission Following Meeting with FDA


11/19/2008 11:12:31 AM

RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc., (Nasdaq: BDSI) announced that the company continues to anticipate a resubmission containing the Risk Evaluation and Mitigation Strategy (REMS) for its lead product ONSOLIS™ to the Food and Drug Administration (FDA) in December following a meeting with the FDA this week.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES